The Membrane Attack Complex (MAC) is the terminal cytolytic structure of the Complement System, formed by sequential assembly of complement proteins C5b, C6, C7, C8, and 10-16 copies of C9, which inserts into target cell membranes creating transmembrane pores approximately 10 nm in diameter. These pores disrupt osmotic balance, causing unregulated influx of water and ions that leads to cell lysis. MAC represents the final common pathway for all three complement activation routes (classical, alternative, lectin) and serves as both a direct antimicrobial weapon and a potent inflammatory signal.
Imagine a construction crew building a missile silo through an enemy fortress wall. First, C5b acts as the surveyor who marks the exact spot on the wall. C6 and C7 arrive as the drilling team, punching through the outer surface and anchoring into the lipid membrane like a foundation spike. C8 then arrives as the foreman who signals for the heavy machinery: 10-16 copies of C9 protein that assemble like interlocking concrete rings, forming a cylindrical tunnel through the entire wall thickness.
Once complete, this tunnel is about 10 nanometers wide—large enough for water and ions to flood through uncontrollably, but the cell can't close the breach. For a bacterium, this is catastrophic: water rushes in, the cell swells like an over-inflated balloon, and bursts. Human cells have emergency repair crews (endocytic machinery, vesicle shedding) that can sometimes cut out the damaged section and patch it, but bacteria lack these tools. Meanwhile, defensive proteins like CD59 on our own cells act as "no-build zones," preventing the construction crew from even starting. This is why MAC kills invaders but usually spares our own tissues—unless those protective markers are missing.
MAC formation proceeds through a precisely orchestrated molecular cascade:
Initiation:
C5 convertase (C4b2a3b or C3bBb3b) cleaves C5 → C5a (anaphylatoxin released) + C5b (remains membrane-associated)
Assembly cascade:
C5b + C6 → C5b6 complex (unstable, must bind C7 rapidly)
C5b6 + C7 → C5b-7 complex (amphipathic, inserts into lipid bilayer)
C5b-7 + C8 → C5b-8 complex (creates small initial pore, ~1 nm diameter)
C5b-8 + C9 (×10-16) → C5b-9 (MAC) with full transmembrane channel
C9 polymerization:
- C8α subunit initiates C9 binding
- First C9 molecule undergoes conformational change from soluble to membrane-inserting form
- Sequential C9 molecules polymerize via hydrophobic interactions
- Final structure: cylindrical pore with 10 nm inner diameter, 16 nm outer diameter
- Polymerization completes within 30-90 seconds of initiation
Regulatory checkpoints:
- CD59 (protectin): binds C5b-8, prevents C9 recruitment and polymerization
- DAF (CD55): accelerates decay of C3 convertases upstream
- Membrane cofactor protein (CD46): inactivates C3b/C4b
- S-protein (vitronectin): binds soluble C5b-7, preventing membrane insertion
- Clusterin: similar to S-protein, creates soluble SC5b-9 complexes
graph TD
A[C5 convertase cleaves C5] --> B["C5b + C5a"]
B --> C[C5b binds C6]
C --> D[C5b6 binds C7]
D --> E[C5b-7 inserts into membrane]
E --> F[C5b-7 binds C8]
F --> G[C5b-8 initiates small pore]
G --> H[First C9 binds and transforms]
H --> I[Sequential C9 polymerization]
I --> J[10-16 C9 molecules form complete MAC]
J --> K[10 nm pore disrupts osmotic balance]
K --> L{Cell type?}
L -->|Bacteria| M[Cell lysis - no repair mechanisms]
L -->|Nucleated cells| N[Endocytosis/vesicle shedding]
N --> O[Potential survival]
P[CD59 on host cells] -.blocks.-> H
Q[Clusterin/S-protein] -.blocks.-> E
style M fill:#ff6b6b
style O fill:#51cf66
style P fill:#4dabf7
style Q fill:#4dabf7
Sub-lytic MAC effects:
When MAC forms at densities insufficient to kill, it triggers:
- Calcium influx → NLRP3 inflammasome activation
- NF-κB signaling → pro-inflammatory cytokine production (IL-6, IL-8)
- MAPK pathway activation → cellular proliferation signals
- Protein kinase C activation → platelet aggregation
Lytic threshold:
- ~1 MAC per μm² cell surface: activation without lysis
-
3-5 MAC per μm²: lethal for most bacteria
- Nucleated mammalian cells can tolerate 5-20 MAC/μm² via repair
MAC dysregulation sits at the intersection of innate immune system overactivation and tissue self-damage, making it clinically relevant across multiple cPNI metamodels:
Metamodel 0 (Evolutionary Mismatch):
The complement system evolved for acute pathogen defense, not chronic low-grade activation. Modern triggers—AGEs, oxidative stress, ischemic tissue, chronic inflammation—cause persistent MAC deposition on host tissues. The system operates as a "selfish immune system": once activated, it doesn't distinguish between bacterial membranes and endothelial cells, particularly when protective regulators (CD59, CD55) are downregulated by inflammatory cytokines or oxidative damage.
Clinical presentations of MAC dysregulation:
-
Paroxysmal Nocturnal Hemoglobinuria (PNH):
- Loss of GPI-anchored proteins (CD55, CD59) on red blood cells
- Uncontrolled MAC assembly on RBC membranes → intravascular hemolysis
- Hemoglobin <7-9 g/dL, elevated LDH >2× upper limit, reduced haptoglobin
- Treatment: eculizumab (anti-C5 monoclonal antibody) blocks C5 cleavage, prevents MAC formation
-
Atypical Hemolytic Uremic Syndrome (aHUS):
- Genetic defects in complement regulators (factor H, factor I, MCP)
- MAC-mediated endothelial injury in renal microvasculature
- Thrombotic microangiopathy, acute kidney injury, hemolysis
- Eculizumab reduces dialysis need from 70% to <10% in acute episodes
-
Age-Related Macular Degeneration (AMD):
- MAC deposits in Bruch's membrane and retinal pigment epithelium
- Sub-lytic MAC induces VEGF secretion → neovascularization
- Polymorphisms in complement regulators (CFH Y402H) increase AMD risk 2.5-7.4×
- Retinal C5b-9 deposition detectable before clinical AMD symptoms
-
Cardiovascular Disease:
- MAC deposition in atherosclerotic plaques accelerates lesion progression
- Ischemia-reperfusion injury: MAC forms within 30-60 minutes of blood flow restoration
- Myocardial MAC deposition correlates with infarct size (r = 0.67, p <0.001)
- Post-MI troponin elevation partly reflects MAC-mediated cardiomyocyte injury
-
Neurodegenerative Disease:
- MAC deposits in Alzheimer's plaques and neurofibrillary tangles
- Chronic sub-lytic MAC on neurons → tau hyperphosphorylation, synaptic loss
- CSF C5b-9 levels >400 ng/mL correlate with cognitive decline rate
- MAC activation in Multiple Sclerosis lesions drives oligodendrocyte death
Infection susceptibility patterns:
- Terminal complement deficiencies (C5-C9): 1,000-10,000× increased risk of Neisseria meningitidis infection
- Paradox: C9 deficiency common in Japan (0.1% population), minimal infection increase—suggests redundancy with other innate immunity mechanisms
- Patients require meningococcal vaccination every 3-5 years, prophylactic antibiotics during outbreaks
Intervention implications:
-
Reduce upstream complement activation:
- Omega-3 fatty acids (EPA 2-4 g/day) reduce alternative pathway C3 convertase formation
- Vitamin D (target 50-80 ng/mL) upregulates CD55/CD59 expression on endothelial cells
- Curcumin 500-1,000 mg/day inhibits C5 convertase assembly (in vitro IC₅₀ = 12 μM)
-
Protect cell membranes:
- Phosphatidylcholine supplementation stabilizes membrane lipid rafts, reduces MAC insertion
- Vitamin E (mixed tocopherols 400-800 IU/day) prevents oxidative CD59 inactivation
-
Minimize ischemia-reperfusion:
- Intermittent Living strategies: brief ischemic preconditioning reduces MAC formation 40-60%
- Avoid sudden high-intensity exercise in deconditioned patients (acute muscle ischemia → MAC-mediated rhabdomyolysis)
-
Address chronic antigen exposure:
- Oral dysbiosis: LPS-IgM complexes activate classical pathway → MAC on gut epithelium
- AGEs from processed foods: AGE-RAGE binding triggers alternative pathway → vascular MAC
Biomarker utility:
- Plasma SC5b-9 (soluble MAC): normal <250 ng/mL, >500 ng/mL indicates active complement consumption
- Urine C5b-9: marker for renal complement activation in lupus nephritis, glomerulonephritis
- Tissue immunofluorescence: MAC deposition pathognomonic for complement-mediated injury
- MAC pore diameter is precisely 10 nm—large enough for Na⁺, K⁺, Ca²⁺, and H₂O, but excludes proteins >40 kDa
- Each complete MAC contains exactly 1 copy each of C5b, C6, C7, C8 and 10-16 copies of C9
- C9 polymerization creates a ring structure with 16 β-barrel transmembrane segments
- Gram-negative bacteria are more MAC-susceptible than Gram-positive (outer membrane vs. thick peptidoglycan)
- Sub-lytic MAC density (1-3 per μm²) activates cells without killing, triggering inflammatory cascades
- CD59 has 100-fold higher affinity for C5b-8 than for C5b-9, making it most effective before C9 addition
- Nucleated cells can internalize and degrade MAC through endocytosis within 15-30 minutes
- Genetic C5 deficiency provides complete protection from MAC but increases meningococcal disease risk 7,000-10,000×
- SC5b-9 (soluble MAC) has 2-4 hour half-life in plasma, making it a real-time complement activity marker
- MAC deposits persist in tissue for 7-21 days, detectable via C5b-9 neoantigen immunostaining
- Eculizumab dosing: 900 mg IV weekly ×4, then 1,200 mg every 2 weeks (blocks >95% of C5 cleavage)
- Terminal complement pathway accounts for 60-80% of bactericidal activity against encapsulated bacteria
- MAC-mediated hemolysis releases free hemoglobin, triggering oxidative stress and nitric oxide scavenging
- Complement System — MAC is the terminal effector mechanism shared by all three activation pathways (classical, alternative, lectin)
- C5a — potent anaphylatoxin generated simultaneously with C5b during MAC initiation, amplifies inflammation via neutrophil chemotaxis
- innate immune system — provides rapid, antibody-independent cell killing mechanism against extracellular pathogens
- CD59 — GPI-anchored host cell protectin that binds C5b-8 and prevents C9 polymerization, essential "self" marker
- inflammation — sub-lytic MAC triggers NLRP3 inflammasome activation, IL-6 and IL-8 secretion, perpetuating inflammatory cascades
- bacteria — primary targets for MAC-mediated lysis, particularly Gram-negative species with exposed outer membranes
- Neisseria — terminal complement deficiencies increase meningococcal infection risk 7,000-10,000×, demonstrating MAC's critical role
- autoimmunity — dysregulated MAC attacks host tissues in paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, lupus nephritis
- ischemia-reperfusion injury — MAC forms within 30-60 minutes of blood flow restoration, contributing 30-50% of total tissue damage
- endothelial cells — vulnerable to MAC deposition during chronic inflammation, driving atherosclerosis and vascular dysfunction
- neurodegeneration — MAC deposits found in Alzheimer's plaques, MS lesions, contributing to synaptic loss and neuronal death
- Alzheimer's Disease — chronic sub-lytic MAC on neurons triggers tau hyperphosphorylation, CSF C5b-9 correlates with cognitive decline
- oxidative stress — inactivates CD59 and CD55 through protein oxidation, removing protective brake on MAC formation
- AGEs — activate alternative pathway via direct binding to C3, increasing MAC deposition on endothelium in diabetes
- Omega-3 fatty acids — EPA/DHA reduce C3 convertase formation and MAC assembly, protective in cardiovascular disease
- Vitamin D — upregulates CD55/CD59 expression, strengthens cellular resistance to MAC-mediated injury
- gut barrier — MAC contributes to epithelial damage in IBD, leaky gut; oral dysbiosis drives chronic complement activation
- Multiple Sclerosis — MAC-mediated oligodendrocyte death in active lesions, potential therapeutic target with complement inhibitors
- chronic inflammation — persistent MAC formation shifts from pathogen defense to tissue injury, exemplifying selfish immune system concept
- Intermittent Living — brief ischemic preconditioning upregulates complement regulators, reducing subsequent MAC formation by 40-60%